• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enrollment of Racial and Ethnic Minoritized Groups in Gynecologic Oncology Clinical Trials: A Review of the Scope of the Problem, Contributing Factors, and Strategies to Improve Inclusion.妇科肿瘤临床试验中少数民族群体的纳入:问题范围、促成因素及改善纳入策略的综述
Clin Obstet Gynecol. 2023 Mar 1;66(1):22-35. doi: 10.1097/GRF.0000000000000765. Epub 2022 Nov 21.
2
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.少数族裔在妇科肿瘤学中代表性不足:对超过 250 项试验的分析。
Gynecol Oncol. 2024 Feb;181:1-7. doi: 10.1016/j.ygyno.2023.12.001. Epub 2023 Dec 13.
3
Racial and Ethnic Inequities in US Oncology Clinical Trial Participation From 2017 to 2022.2017 年至 2022 年美国肿瘤学临床试验参与中的种族和民族不平等。
JAMA Netw Open. 2023 Jul 3;6(7):e2322515. doi: 10.1001/jamanetworkopen.2023.22515.
4
Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials.医学学术文献:《低英语水平患者参与妇科肿瘤临床试验》
J Natl Compr Canc Netw. 2023 Jan;21(1):27-32.e2. doi: 10.6004/jnccn.2022.7068.
5
Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials.少数族裔个体参与妇科癌症精准肿瘤学试验。
Obstet Gynecol. 2022 Oct 1;140(4):654-661. doi: 10.1097/AOG.0000000000004917. Epub 2022 Sep 7.
6
US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials.美国癌症卓越中心增加临床试验中少数族裔参与的策略。
J Oncol Pract. 2019 Apr;15(4):e289-e299. doi: 10.1200/JOP.18.00638. Epub 2019 Mar 4.
7
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors.免疫检查点抑制剂临床试验中少数族裔种族和民族群体的代表性不足及报告不足
JCO Oncol Pract. 2025 Mar;21(3):408-417. doi: 10.1200/OP.24.00033. Epub 2024 Aug 22.
8
Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.聚(ADP - 核糖)聚合酶抑制剂用于妇科癌症临床试验中的种族和族裔入组差异。
Gynecol Oncol. 2022 Apr;165(1):49-52. doi: 10.1016/j.ygyno.2022.01.032. Epub 2022 Feb 8.
9
Diversity and transparency in gynecologic oncology clinical trials.妇科肿瘤学临床试验中的多样性与透明度
Cancer Causes Control. 2023 Feb;34(2):133-140. doi: 10.1007/s10552-022-01646-y. Epub 2022 Oct 25.
10
Demographic reporting and language exclusion in gynecologic oncology clinical trials.妇科肿瘤临床试验中的人口统计学报告和语言排除。
Am J Obstet Gynecol. 2024 Jan;230(1):73.e1-73.e14. doi: 10.1016/j.ajog.2023.09.019. Epub 2023 Sep 24.

引用本文的文献

1
Innovative Development of Research Engagement Manual: Strategies to Enhance Recruitment and Retention of Black Individuals in Clinical Trials for Substance Use Disorders.《研究参与手册的创新发展:提高黑人个体参与物质使用障碍临床试验的招募与留存率的策略》
Health Equity. 2025 Aug 22;9(1):387-396. doi: 10.1177/24731242251362181. eCollection 2025.
2
Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer.转变治疗模式:聚焦高级别浆液性卵巢癌的个性化医疗。
CA Cancer J Clin. 2025 Apr 19. doi: 10.3322/caac.70008.
3
Principal investigator gender and clinical trial success: analysis of over 3000 obstetrics and gynecology trials.主要研究者性别与临床试验成功率:对3000多项妇产科试验的分析
AJOG Glob Rep. 2024 Dec 4;5(1):100427. doi: 10.1016/j.xagr.2024.100427. eCollection 2025 Feb.
4
Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US.美国妇科肿瘤学临床试验可及性的地理差异。
JAMA Netw Open. 2024 Nov 4;7(11):e2447635. doi: 10.1001/jamanetworkopen.2024.47635.
5
Barriers to Recruitment and Retention Among Underrepresented Populations in Cancer Clinical Trials: A Qualitative Study of the Perspectives of Clinical Trial Research Coordinating Staff at a Cancer Center.癌症临床试验中代表性不足人群的招募与留用障碍:对某癌症中心临床试验研究协调人员观点的定性研究
J Healthc Leadersh. 2024 Nov 1;16:427-441. doi: 10.2147/JHL.S488426. eCollection 2024.
6
Strategies for increasing accrual in cancer clinical trials: What is the evidence?增加癌症临床试验入组率的策略:有哪些证据?
Cancer Med. 2024 May;13(10):e7298. doi: 10.1002/cam4.7298.
7
Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer.妇科癌症女性患者参与临床试验中的种族和民族差异。
JAMA Netw Open. 2023 Dec 1;6(12):e2346494. doi: 10.1001/jamanetworkopen.2023.46494.
8
Experiences and preferences for learning about neonatal research: insights from parent interviews.关于新生儿研究学习的经历与偏好:来自家长访谈的见解
J Perinatol. 2024 Mar;44(3):404-414. doi: 10.1038/s41372-023-01790-6. Epub 2023 Nov 25.

妇科肿瘤临床试验中少数民族群体的纳入:问题范围、促成因素及改善纳入策略的综述

Enrollment of Racial and Ethnic Minoritized Groups in Gynecologic Oncology Clinical Trials: A Review of the Scope of the Problem, Contributing Factors, and Strategies to Improve Inclusion.

机构信息

Department of Obstetrics & Gynecology.

Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine.

出版信息

Clin Obstet Gynecol. 2023 Mar 1;66(1):22-35. doi: 10.1097/GRF.0000000000000765. Epub 2022 Nov 21.

DOI:10.1097/GRF.0000000000000765
PMID:36657045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9869456/
Abstract

Racial inequities are well-documented across the gynecologic oncology care continuum, including the representation of racial and ethnic minoritized groups (REMGs) in gynecologic oncology clinical trials. We specifically reviewed the scope of REMG disparities, contributing factors, and strategies to improve inclusion. We found systematic and progressively worsening under-enrollment of REMGs, particularly of Black and Latinx populations. In addition, race/ethnicity data reporting is poor, yet a prerequisite for accountability to recruitment goals. Trial participation barriers are multifactorial, and successful remediation likely requires multi-level strategies. More rigorous, transparent data on trial participants and effectiveness studies on REMG recruitment strategies are needed to improve enrollment.

摘要

种族不平等现象在妇科肿瘤学护理连续体中得到了充分的记录,包括在妇科肿瘤学临床试验中少数民族群体(REMGs)的代表性。我们特别审查了 REMG 差异的范围、促成因素以及改善包容性的策略。我们发现 REMGs 的系统性和逐渐恶化的参与不足,特别是黑人族裔和拉丁裔人口。此外,种族/族裔数据报告很差,但这是对招募目标负责的前提。试验参与障碍是多方面的,成功的补救措施可能需要多层次的策略。需要更严格、透明的试验参与者数据和针对 REMG 招募策略的有效性研究,以提高参与率。